Relevant bibliographies by topics / Cancer cells – Proliferation / Books

Books on the topic 'Cancer cells – Proliferation'

To see the other types of publications on this topic, follow the link: Cancer cells – Proliferation.
Author: Grafiati
Published: 4 June 2021
Last updated: 11 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 books for your research on the topic 'Cancer cells – Proliferation.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse books on a wide variety of disciplines and organise your bibliography correctly.

1

Enders, Greg H. Cell cycle deregulation in cancer. New York: Springer, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

M, Soto A., ed. The society of cells: Cancer control of cell proliferation. Oxford: Bios Scientific Publishers, 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Sonnenschein, C. The society of cells: Cancer and control of cell proliferation. Oxford: Bios Scientific Publishers, 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Ito, Takaaki. Differentiation and proliferation of pulmonary neuroendocrine cells. Jena, Germany: Urban & Fischer, 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Cancer Stem Cell Workshop (2007? Berlin-Brandenburg Academy of Sciences and Humanities). Cancer stem cells: Novel concepts and prospects for tumor therapy. Edited by Wiestler O. D. 1956-, Haendler B, and Mumberg D. Berlin: Springer, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Cancer Stem Cell Workshop (2007? Berlin-Brandenburg Academy of Sciences and Humanities). Cancer stem cells: Novel concepts and prospects for tumor therapy. Edited by Wiestler O. D. 1956-, Haendler B, and Mumberg D. Berlin: Springer, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Meridith, Alan T. Handbook of prostate cancer cell research: Growth, signalling, and survival. New York: Nova Biomedical Books, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Handbook of prostate cancer cell research: Growth, signalling, and survival. New York: Nova Biomedical Books, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

V, Pavlova Lyudmila, and Yakovlev Andrej Yu 1944-, eds. Biomathematical problems in optimization of cancer radiotherapy. Boca Raton: CRC Press, 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Ludlow, John W. Tumor suppressors: Involvement in human diseases, viral protein interactions, and growth regulation. Austin: R.G. Landes, 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
11

1943-, Ford Richard J., Maizel Abby L, and M.D. Anderson Hospital and Tumor Institute., eds. Mediators in cell growth and differentiation. New York: Published for the University of Texas M.D. Anderson Hospital and Tumor Institute at Houston, Houston, Tex., by Raven Press, 1985.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
12

Resende, Rodrigo R., and Henning Ulrich, eds. Trends in Stem Cell Proliferation and Cancer Research. Dordrecht: Springer Netherlands, 2013. http://dx.doi.org/10.1007/978-94-007-6211-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
13

S, Lakshmi M., ed. The genetics of cancer: Genes associated with cancer invasion, metastasis, and cell proliferation. San Diego: Academic Press, 1997.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
14

Pereira, Michael A. Effect of dichloroacetic acid and trichloroacetic acid on cell proliferation in B6C3F1 mice. Denver, CO: AWWA Research Foundation and American Water Works Association, 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
15

APOPTOSIS AND CELL CONTROL IN CANCER (Ucl Molecular Pathology). Garland Science, 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
16

Avner, Friedman, and Aguda B, eds. Cell cycle, proliferation, and cancer. Berlin: Springer, 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
17

Apoptosis and cell cycle control in cancer: Basic mechanisms and implications for treating malignant disease. Oxford: BIOS Scientific, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
18

M, García-Caballero, Brandes L. J, and Hosoda S, eds. Histamine in normal and cancer cell proliferation. Oxford: Pergamon Press, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
19

Sonnenschein, Pr. The Society of Cells: Cancer and Control of Cell Proliferation. Garland Science, 1998.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
20

L, Boynton Alton, and Leffert H. L, eds. Control of animal cell proliferation. Orlando: Academic Press, 1985.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
21

L, Boynton Alton, and Leffert Hyam L, eds. Control of animal cell proliferation. Academic, 1987.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
22

P, Briggs Andre, and Coburn Jacob A, eds. Handbook of cell proliferation. Hauppauge, NY: Nova Science Publishers, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
23

Nicolini, Claudio A. Cell Growth. Springer, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
24

(Editor), O. D. Wiestler, B. Haendler (Editor), and D. Mumberg (Editor), eds. Cancer Stem Cells: Novel Concepts and Prospects for Tumor Therapy (Ernst Schering Foundation Symposium Proceedings). Springer, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
25

L, Pusztai, Lewis Claire E, and Yap E, eds. Cell proliferation in cancer: Regulatory mechanisms of neoplastic cell growth. Oxford: Oxford University Press, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
26

Growth, Cancer, and the Cell Cycle: The Molecular, Cellular, and Developmental Biology. Humana Press, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
27

1924-, Frei Emil, and Bristol-Myers Symposium on Cancer Research (10th : 1987 : Boston, Mass.), eds. The Regulation of proliferation and differentiation in normal and neoplastic cells. San Diego: Academic Press, 1989.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
28

HALL, PETER ED. Assessment Of Cell Proliferation In Clinical Practice. Springer, 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
29

(Editor), Peter A. Hall, D. A. Levison (Editor), and N. A. Wright (Editor), eds. Assessment of Cell Proliferation in Clinical Practice. Springer-Verlag Berlin and Heidelberg GmbH & Co. K, 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
30

(Editor), Lajos Pusztai, C. E. Lewis (Editor), and Eric Yap (Editor), eds. Cell Proliferation in Cancer: Regulatory Mechanisms of Neoplastic Cell Growth (Oxford Medical Publications). Oxford University Press, USA, 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
31

T, Meridith Alan, ed. Handbook of prostate cancer cell research: Growth, signalling, and survival. Hauppauge, NY: Nova Science, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
32

B, Kastan M., and Imperial Cancer Research Fund (Great Britain), eds. Checkpoint controls and cancer. Plainview, NY: Cold Spring Harbor Laboratory Press, 1997.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
33

Avner, Friedman, and Aguda B, eds. Tutorials in mathematical biosciences. Berlin: Springer, 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
34

Wei, Dai, ed. Checkpoint responses in cancer therapy. Totowa, NJ: Humana Press, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
35

Eisen, Tim. The patient with renal cell cancer. Edited by Giuseppe Remuzzi. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199592548.003.0172.

Full text
Abstract:
Renal cancer is the commonest malignancy of the kidney and worldwide, accounts for between 2% and 3% of the total cancer burden. The mainstay of curative treatment remains surgery. There have been significant advances in surgical technique, the most important ones being nephron-sparing surgery and laparoscopic nephrectomy. The medical treatment of advanced renal cell cancer has only improved markedly in the last decade with the development of antiangiogenic tyrosine-kinase inhibitors, inhibitors of mammalian target of rapamycin, and a diminished role for immunotherapy.Tyrosine-kinase inhibitor therapy results in reduction of tumour volume in around three-quarters of patients and doubles progression-free survival, but treatment is not curative. The management of side effects in patients on maintenance tyrosine-kinase inhibitors has improved in the last 3 years, although still presents difficulties which have to be actively considered.The molecular biology of renal cell carcinoma is better understood than for the majority of solid tumours. The commonest form of renal cancer, clear-cell carcinoma of the kidney, is strongly associated with mutations in the von Hippel–Lindau gene and more recently with chromatin-remodelling genes such as PBRM1. These genetic abnormalities lead to a loss of control of angiogenesis and uncontrolled proliferation of tumour cells. There is a very wide spectrum of tumour behaviour from the extremely indolent to the terribly aggressive. It is not currently known what accounts for this disparity in tumour behaviour.A number of outstanding questions are being addressed in scientific and clinical studies such as a clearer understanding of prognostic and predictive molecular biomarkers, the role of adjuvant therapy, the role of surgery in the presence of metastatic disease, how best to use our existing agents, and investigation of novel targets and therapeutic agents, especially novel immunotherapies.
APA, Harvard, Vancouver, ISO, and other styles
36

Josephs, Debra H., Heather J. Bax, Giulia Pellizzari, James F. Spicer, Ana Montes, and Sophia N. Karagiannis. Antibody Therapeutics for Ovarian Carcinoma and Translation to the Clinic. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190248208.003.0001.

Full text
Abstract:
Despite improvements over the past decade in the treatment of ovarian cancer, many patients are at risk of recurrent disease and emerging drug resistance. The increased selectivity and reduced toxicity of molecularly targeted anti-cancer agents renders them attractive for development in ovarian cancer, and monoclonal antibodies targeting ovarian cancer-specific tumor antigens represent the largest such group investigated in this clinical setting. This chapter describes examples of monoclonal antibodies clinically evaluated for efficacy in ovarian cancer. These agents recognize molecular targets expressed on tumors or within tumor microenvironments that may be essential for tumor cell survival and proliferation. Recently, antibodies targeting checkpoint molecules on immune cells have shown efficacy in modulating anti-tumor immunity, and applications in ovarian carcinomas are evaluated. The chapter focuses on therapeutic agents’ attributes on targeting key cancer growth and progression pathways, and propensity to engender effector functions by activating immune effector cells in tumors and the circulation.
APA, Harvard, Vancouver, ISO, and other styles
37

Ajithkumar, Thankamma, Ann Barrett, Helen Hatcher, and Natalie Cook. Paediatric malignancies. Oxford University Press, 2011. http://dx.doi.org/10.1093/med/9780199235636.003.0015.

Full text
Abstract:
Leukaemia is the commonest cancer (accounting for >40% of cases) in children. It is a clonal proliferation of stem cells which leads to bone marrow failure and tissue infiltration.• Acute lymphoblastic leukaemia (ALL): 4/100,000• Acute myeloid leukaemia (AML): 0.7/100,000• Chronic myeloid leukaemia (CML): 0.2/100,000...
APA, Harvard, Vancouver, ISO, and other styles
38

Skuse, Gary R., and John W. Ludlow. Tumor Suppressors: Involvement in Human Diseases, Viral Protein Interactions and Growth Regulation (Molecular Biology Intelligence Unit). R G Landes Co, 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
39

Bertolaso, Marta, and John Dupré. A Processual Perspective on Cancer. Oxford University Press, 2018. http://dx.doi.org/10.1093/oso/9780198779636.003.0016.

Full text
Abstract:
This chapter attempts to illuminate the dynamic stability of the organism and the robustness of its developmental pathway by considering the biology of cancer. Healthy development and stable functioning of a multicellular organism require an exquisitely regulated balance between processes of cell division, differentiation, and death (apoptosis). Cancer involves a disruption of this balance, which results in unregulated cell proliferation. The thesis defended in this chapter is that the coupling between proliferation and differentiation, whether normal or pathological (as in cancer), is best understood within a process-ontological framework. This framework emphasizes the interactions and mutual stabilizations between processes at different levels and this, in turn, explains the difficulty in allocating the neoplastic process to any particular level (genetic, epigenetic, cellular, or histological). Understanding these interactions is likely to be a precondition of a proper understanding of how these mutual regulations are disrupted in the processes we call cancerous.
APA, Harvard, Vancouver, ISO, and other styles
40

Freifeld, Alison G. An Introduction. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199938568.003.0100.

Full text
Abstract:
This chapter focuses on solid tumors and how they can be treated. Solid tumors, lymphomas, and leukemias represent a widely diverse array of cancers. Until recently, the general approach to treating all of them was to administer cytotoxic anticancer drugs that damage proliferating cells by interfering with mitosis and other essential steps in cellular replication. Localized solid tumors are largely treated by surgical resection and radiotherapy, with cytotoxic chemotherapy being commonly used adjunctively or in cases of metastatic disease. A major drawback of this approach has been the lack of specificity in that cytotoxic drugs will destroy actively dividing normal cells as well as malignant cells. The “shotgun approach” of using intensive cytotoxic chemotherapies has been the mainstay of cancer treatment for at least 6 decades. The chapter concludes that in addition to the tissue damage and immunomodulating effects of anticancer drugs, it should be remembered that cancers themselves may increase the chances for infection.
APA, Harvard, Vancouver, ISO, and other styles
41

Brinton, Louise A., Mia M. Gaudet, and Gretchen L. Gierach. Breast Cancer. Oxford University Press, 2017. http://dx.doi.org/10.1093/oso/9780190238667.003.0045.

Full text
Abstract:
Breast cancer is the most frequently diagnosed cancer in women worldwide, with annual estimates of 1.7 million newly diagnosed cases and 522,000 deaths. Although more breast cancers are diagnosed in economically developed than in developing countries, the reverse is true for mortality, reflecting limited screening and less effective treatments in the latter. Breast cancer incidence has been on the rise in the United States for many years, but in recent years this is restricted to certain subgroups, while internationally there have been continued generalized increases, likely reflecting adoption of more Westernized lifestyles. Breast cancer is widely recognized as being hormonally influenced, with most of the established risk factors believed to reflect the influence of cumulative exposure of the breast to stimulatory effects of ovarian hormones—leading to increased cellular proliferation, which in turn can result in genetic errors during cell division.
APA, Harvard, Vancouver, ISO, and other styles
42

Bisen, Prakash S., Zakir Khan, and Saurabh Bundela. Biology of Oral Cancer: Key Apoptotic Regulators. Taylor & Francis Group, 2013.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
43

Bisen, Prakash S., Zakir Khan, and Saurabh Bundela. Biology of Oral Cancer: Key Apoptotic Regulators. Taylor & Francis Group, 2017.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
44

Girod, Sabine C., and Sabine Christiane Girod. Tumor Suppressor Genes and Cell Proliferation Control in the Carcinogenesis of the Oral Mucosa. QUINTESSENCE, 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
45

Tutorials in Mathematical Biosciences III: Cell Cycle, Proliferation, and Cancer (Lecture Notes in Mathematics Book 1872). Springer, 2005.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
46

(Contributor), B. Aguda, M. Chaplain (Contributor), A. Friedman (Contributor), M. Kimmel (Contributor), H. A. Levine (Contributor), G. Lolas (Contributor), A. Matzavinos (Contributor), M. Nilsen-Hamilton (Contributor), A. Swierniak (Contributor), and Avner Friedman (Editor), eds. Tutorials in Mathematical Biosciences III: Cell Cycle, Proliferation, and Cancer (Lecture Notes in Mathematics / Mathematical Biosciences Subseries). Springer, 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
47

Hodgkiss, Andrew. Further clinical issues. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780198759911.003.0012.

Full text
Abstract:
The clinical challenges arising when a person with a severe mental illness, such as schizophrenia or bipolar disorder, develops a cancer are surveyed. Delayed diagnosis and access to oncological treatment, factors contributing to reduced adherence, and the interruption of specialist community psychiatric care are discussed. Long-term psychotropic medication may complicate end-of-life care, and access to palliative care is usually limited for those in secure mental health inpatient units. The striking inverse relationship between neurodegenerative disorders (Alzheimer-type dementia) and proliferative disorders (cancers) is considered.Psychiatric aspects of haematopoietic stem cell transplantation (HSCT) are reviewed, including psychopathology arising from drugs used to prevent graft-versus-host disease and from infections complicating chronic immunosuppression. Cognitive impairment and suicide after HSCT are considered.
APA, Harvard, Vancouver, ISO, and other styles
48

Transforming Growth Factor-Beta in Cancer Therapy: Volume II (Cancer Drug Discovery and Development). Humana Press, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
49

Grant, Warren, and Martin Scott-Brown. Prevention of cancer. Edited by Patrick Davey and David Sprigings. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199568741.003.0350.

Full text
Abstract:
In the UK, the four commonest cancers—lung cancer, breast cancer, colon cancer, and prostate cancer—result in around 62 000 deaths every year. Although deaths from cancer have fallen in the UK over the last 20 years, the UK still suffers from higher cancer death rates than many other countries in Western Europe. In 1999, the UK government produced a White Paper called Saving Lives: Our Healthier Nation that outlined a national target to reduce the death rate from cancer by at least 20% in people under 75 by 2010. The subsequent NHS Cancer Plan of 2000 designed a framework by which to achieve this target through effective prevention, screening, and treatment programmes as well as restructuring and developing new diagnostic and treatment facilities. But do we know enough about the biology of the development of cancer for government health policies alone to force dramatic changes in survival? The science behind the causes of cancer tells us that its origin lies in acquired or inherited genetic abnormalities. Inherited gene mutation syndromes and exposure to environmental mutagens cause cancer, largely through abnormalities in DNA repair mechanisms, leading to uncontrolled cell proliferation. Although screening those thought to be at highest risk, and regulating exposure to environmental carcinogens such as tobacco or ionizing radiation, have reduced, and will continue to reduce, cancer deaths, there are many other environmental factors that have been shown to increase the population risk of cancer. These will be outlined in this chapter. However, the available evidence is largely from retrospective and cross-sectional population-based studies and therefore limits the ability to apply this knowledge to the risk of the individual patient who may been seen in clinic. Although we may be able to put him or her into a high-, intermediate-, or low-risk category, the question ‘will I get cancer, doc?’ is one that we cannot answer with certainty. The NHS Cancer Plan of 2000, designed to reduce cancer deaths in this country and to bring UK treatment results in line with those other countries in Europe, focuses on preventing malignancy as part of its comprehensive cancer management strategy. It highlights that the rich are less likely to develop cancer, and will survive longer if they are diagnosed than those who live in poverty. This may reflect available treatment options, but is more likely to be related to the lifestyle of those with regular work, as they may be more health aware. The Cancer Plan, however, suggests that relieving poverty may be more labour intensive and less rewarding than encouraging positive risk-reducing behaviour in all members of the population. Eating well can reduce the risk of developing many cancers, particularly of the stomach and bowel. The Cancer Plan outlines the ‘Five-a-Day’ programme which was rolled out in 2002 and encouraged people to eat at least five portions of fruit and vegetables per day. Obese people are also at higher risk of cancers, in particular endometrial cancer. A good diet and regular exercise not only reduce obesity but are also independent risk-reducing factors. Alcohol misuse is thought to be a major risk factor in around 3% of all cancers, with the highest risk for cancers of the mouth and throat. As part of the Cancer Plan, the Department of Health promotes physical activity and general health programmes, as well as alcohol and smoking programmes, particularly in deprived areas. Focusing on these healthy lifestyle points can potentially reduce an individual lifetime risk of all cancers. However, our knowledge of the biology of four cancers in particular has led to the development of specific life-saving interventions. Outlined in this chapter are details regarding ongoing prevention strategies for carcinomas of the lung, the breast, the bowel, and the cervix.
APA, Harvard, Vancouver, ISO, and other styles
50

Transforming Growth Factor-Beta in Cancer Therapy: Volume I, Basic and Clinical Biology (Cancer Drug Discovery and Development). Humana Press, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the bibliographies on the topic 'Cancer cells – Proliferation' for other source types:
Journal articles Dissertations / Theses
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography